This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study
by Zacks Equity Research
AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.
AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi
by Zacks Equity Research
AstraZeneca (AZN) to sell U.S. rights of Synagis to Sobi for an upfront consideration of $1.5 billion as it streamlines its portfolio
The Zacks Analyst Blog Highlights: Berkshire Hathaway, AbbVie, Booking, HCA and Kimberly-Clark
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, AbbVie, Booking, HCA and Kimberly-Clark
Top Research Reports for Berkshire Hathaway, AbbVie & Booking Holdings
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), AbbVie (ABBV) and Booking Holdings (BKNG).
Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Momenta (MNTA) posts narrower-than-expected loss in the third quarter, while revenues fall short of estimates.
Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
by Zacks Equity Research
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $87.73, moving +0.89% from the previous trading session.
AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up
by Zacks Equity Research
AbbVie's (ABBV) Q3 earnings top estimates while revenues fall short. Revenues increase year over year on strong sales growth of Humira, Imbruvica and Mavyret.
AbbVie (ABBV) Tops Q3 Earnings Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 6.47% and -0.28%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
by Zacks Equity Research
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Neurocrine (NBIX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are expected to focus on Neurocrine's (NBiX) updates on its pipeline candidates when it reports third-quarter results.
What's in the Cards for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret are expected to drive third-quarter sales.
Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO
by Zacks Equity Research
Merck (MRK) and Bristol-Myers (BMY) report mixed third-quarter results. Pharma bigwigs present cancer data at ESMO.
AbbVie (ABBV) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J Intends to Buy Residual Stake in Japanese Skincare Firm
by Zacks Equity Research
Johnson & Johnson (JNJ) makes a tender offer to buy the leftover stake in Japanese skincare firm Ci:z Holdings for about $2.05 billion in cash to strengthen its dermatology portfolio.
Healthcare ETFs to Buy Ahead of Q3 Earnings
by Sweta Killa
The positive estimate revisions suggest continued outperformance for the healthcare ETFs.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $82.96, moving -1.55% from the previous trading session.
Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines
by Zacks Equity Research
Biogen beat estimates for both earnings and sales in the third quarter. Its newest drug Spinraza performs well in the quarter.
Novartis Reports Positive Long-Term Data From Cosentyx Trials
by Zacks Equity Research
Novartis (NVS) announces encouraging five-year data from late-stage studies on Cosentyx for psoriatic arthritis and ankylosing spondylitis indications.
EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq
by Zacks Equity Research
EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.
J&J (JNJ) Beats Earnings & Sales Estimates in Q3, Ups View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the third quarter of 2018 and raises full-year forecast.
Company News For Oct 15, 2018
by Zacks Equity Research
Companies In The News are: FRC,PNC,ABBV,INTC
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
by Zacks Equity Research
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
Bristol-Myers Inks Deal and Invests $12 Million in Compugen
by Zacks Equity Research
Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.
AbbVie Settles With Novartis to Delay Humira Biosimilar in US
by Zacks Equity Research
AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.